- Home
- MOLN vs CNTB Comparison
MOLN vs CNTB Comparison
Compare MOLN & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MOLN | CNTB |
|---|---|---|
| Founded | 2004 | 2012 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 154.2M | 135.7M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MOLN | CNTB |
|---|---|---|
| Price | $4.12 | $2.23 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $8.38 | ★ $8.67 |
| AVG Volume (30 Days) | 1.1K | ★ 466.9K |
| Earning Date | 05-12-2026 | 08-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $64,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $374.07 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.46 | $1.23 |
| 52 Week High | $5.36 | $3.82 |
Technical Indicators
Market Signals| Indicator | MOLN | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 52.06 | 50.16 |
| Support Level | $3.94 | $1.99 |
| Resistance Level | $4.13 | $2.64 |
| Average True Range (ATR) | 0.07 | 0.12 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 62.28 | 54.02 |
Price Performance
Historical ComparisonAbout MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.